During the last session, ImmunityBio, Inc. (NASDAQ:IBRX)’s traded shares were 1,838,149, with the beta value of the company hitting 2.27. At the end of the trading day, the stock’s price was $18.74, reflecting an intraday loss of -0.29% or -$0.06. The 52-week high for the IBRX share is $45.42, that puts it down -142.37% from that peak though still a striking +85.11% gain since the share price plummeted to a 52-week low of $2.79. The company’s market capitalization is $7.18 Billion, and the average intraday trading volume over the past 10 days was 1.46 Million shares, and the average trade volume was 1.46 Million shares over the past three months.
ImmunityBio, Inc. (IBRX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2. IBRX has a Sell rating from none of the analyst(s) out of 1 analysts who have looked at this stock. Neither of the analyst(s) recommend to Hold the stock while none of them suggest Overweight, and 1 recommend a Buy rating for it. None of the analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.41.
ImmunityBio, Inc. (NASDAQ:IBRX): Trading Information
ImmunityBio, Inc. (IBRX) registered a -0.29% downside in the last session and has traded in the red over the past 5 sessions. The stock spiked 21.75% in intraday trading to $23.95 this Thursday, Apr 01, hitting a weekly high. The stock’s 5-day price performance is -21.09%, and it has moved by -30.07% in 30 days. Despite these dips, the overall price performance for the year is 40.59%. The short interest in ImmunityBio, Inc. (NASDAQ:IBRX) is 4.46 Million shares and it means that shorts have 3.05 day(s) to cover.
The consensus price target of analysts on Wall Street is $25, which implies an increase of 33.4% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $25 and $25 respectively. As a result, IBRX is trading at a discount of 33.4% off the target high and 33.4% off the low.
ImmunityBio, Inc. (IBRX) projections and forecasts
Statistics show that ImmunityBio, Inc. has outperformed its competitors in share price, compared to the industry in which it operates. ImmunityBio, Inc. (IBRX) shares have gone up +137.52% during the last six months. Yet analysts are winding down their growth forecast for the fiscal year 2021. Revenue is predicted to decline -115.8% this quarter and then jump 40% in the quarter after that. In the rating firms’ projections, revenue will decline -9.9% compared to the previous financial year.
Revenue for the current quarter is expected to be $20Million as predicted by 1 analyst(s). Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to $20Million by the end of June 2021. As per earnings report from last fiscal year’s results, sales for the corresponding quarter totaled $21Million. In this case, analysts expect current quarter sales to lessen by -4.8%.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 23.1%. While earnings are projected to return -27.8% in 2021, the next five years will return -1.7% per annum.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.